Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease : A GETAID multicentre cohort study
© 2022 John Wiley & Sons Ltd..
BACKGROUND: Phase III trials have demonstrated the efficacy of risankizumab in moderate-to-severe Crohn's disease (CD), but no real-world data are currently available. We aimed to assess the short-term effectiveness and safety of risankizumab in patients with CD.
METHODS: From May 2021 to May 2022, all patients with refractory luminal CD treated with risankizumab in 22 French GETAID centres were retrospectively included. The primary endpoint was steroid-free clinical remission at week 12 (Harvey-Bradshaw [HB] score <5). Secondary endpoints included clinical response (≥3-point decrease of HB score and/or (HB) score <5), biochemical remission (CRP ≤ 5 mg/L), need for CD-related surgery and adverse events.
RESULTS: Among the 100 patients included, all have been previously exposed to anti-TNF agents, 94 to vedolizumab, 98 to ustekinumab (all exposed to at least three biologics) and 61 had a previous intestinal resection. All but three (97%) received a 600 mg risankizumab intravenous induction at weeks 0-4-8. At week 12, steroid-free clinical remission was observed in 45.8% of patients, clinical remission in 58% and clinical response in 78.5%. In subgroup analysis restricted to patients with objective signs of inflammation at baseline (n = 79), steroid-free clinical remission at week 12 was observed in 39.2% of patients. Biochemical remission was observed in 50% of patients. Six patients discontinued risankizumab before the week 12 visit due to lack of efficacy. CD-related hospitalisation was needed in six patients, and three underwent intestinal resection. In multivariable analysis, only a history of ustekinumab loss of response (vs primary failure) (odds ratio (OR), 2.80; 95% CI: 1.07-7.82; p = 0.041) was significantly associated with clinical remission at week 12. Twenty adverse events (AE) occurred in 20 patients including 7 serious AE corresponding to 6 CD exacerbation and one severe hypertension.
CONCLUSION: In a cohort of highly refractory patients with luminal CD and multiple prior drug failures including ustekinumab, risankizumab induction provided a clinical response in about 3 out of 4 patients and steroid-free clinical remission in about half of patients.
| Errataetall: |
CommentIn: Aliment Pharmacol Ther. 2023 Apr;57(8):909-910. - PMID 36952268 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 57(2023), 4 vom: 09. Feb., Seite 426-434 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fumery, Mathurin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
90ZX3Q3FR7 |
|---|
| Anmerkungen: |
Date Completed 31.01.2023 Date Revised 09.05.2023 published: Print-Electronic CommentIn: Aliment Pharmacol Ther. 2023 Apr;57(8):909-910. - PMID 36952268 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.17358 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350465657 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350465657 | ||
| 003 | DE-627 | ||
| 005 | 20231226045049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.17358 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350465657 | ||
| 035 | |a (NLM)36534763 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fumery, Mathurin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease |b A GETAID multicentre cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2023 | ||
| 500 | |a Date Revised 09.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Aliment Pharmacol Ther. 2023 Apr;57(8):909-910. - PMID 36952268 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Phase III trials have demonstrated the efficacy of risankizumab in moderate-to-severe Crohn's disease (CD), but no real-world data are currently available. We aimed to assess the short-term effectiveness and safety of risankizumab in patients with CD | ||
| 520 | |a METHODS: From May 2021 to May 2022, all patients with refractory luminal CD treated with risankizumab in 22 French GETAID centres were retrospectively included. The primary endpoint was steroid-free clinical remission at week 12 (Harvey-Bradshaw [HB] score <5). Secondary endpoints included clinical response (≥3-point decrease of HB score and/or (HB) score <5), biochemical remission (CRP ≤ 5 mg/L), need for CD-related surgery and adverse events | ||
| 520 | |a RESULTS: Among the 100 patients included, all have been previously exposed to anti-TNF agents, 94 to vedolizumab, 98 to ustekinumab (all exposed to at least three biologics) and 61 had a previous intestinal resection. All but three (97%) received a 600 mg risankizumab intravenous induction at weeks 0-4-8. At week 12, steroid-free clinical remission was observed in 45.8% of patients, clinical remission in 58% and clinical response in 78.5%. In subgroup analysis restricted to patients with objective signs of inflammation at baseline (n = 79), steroid-free clinical remission at week 12 was observed in 39.2% of patients. Biochemical remission was observed in 50% of patients. Six patients discontinued risankizumab before the week 12 visit due to lack of efficacy. CD-related hospitalisation was needed in six patients, and three underwent intestinal resection. In multivariable analysis, only a history of ustekinumab loss of response (vs primary failure) (odds ratio (OR), 2.80; 95% CI: 1.07-7.82; p = 0.041) was significantly associated with clinical remission at week 12. Twenty adverse events (AE) occurred in 20 patients including 7 serious AE corresponding to 6 CD exacerbation and one severe hypertension | ||
| 520 | |a CONCLUSION: In a cohort of highly refractory patients with luminal CD and multiple prior drug failures including ustekinumab, risankizumab induction provided a clinical response in about 3 out of 4 patients and steroid-free clinical remission in about half of patients | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a effectiveness | |
| 650 | 4 | |a induction therapy | |
| 650 | 4 | |a risankizumab | |
| 650 | 7 | |a risankizumab |2 NLM | |
| 650 | 7 | |a 90ZX3Q3FR7 |2 NLM | |
| 650 | 7 | |a Ustekinumab |2 NLM | |
| 650 | 7 | |a FU77B4U5Z0 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 700 | 1 | |a Defrance, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Roblin, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Altwegg, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Caron, Benedicte |e verfasserin |4 aut | |
| 700 | 1 | |a Hébuterne, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Stefanescu, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Nachury, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Laharie, David |e verfasserin |4 aut | |
| 700 | 1 | |a Nancey, Stephane |e verfasserin |4 aut | |
| 700 | 1 | |a Le Berre, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Serrero, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Geyl, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Giletta, Cyrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Ah-Soune, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Duveau, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Uzzan, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Abitbol, Vered |e verfasserin |4 aut | |
| 700 | 1 | |a Biron, Amelie |e verfasserin |4 aut | |
| 700 | 1 | |a Tran-Minh, My-Linh |e verfasserin |4 aut | |
| 700 | 1 | |a Paupard, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Vuitton, Lucine |e verfasserin |4 aut | |
| 700 | 1 | |a Elgharabawy, Yasmine |e verfasserin |4 aut | |
| 700 | 1 | |a Peyrin-Biroulet, Laurent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 57(2023), 4 vom: 09. Feb., Seite 426-434 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2023 |g number:4 |g day:09 |g month:02 |g pages:426-434 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.17358 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2023 |e 4 |b 09 |c 02 |h 426-434 | ||